HER2 in Gastric Cancer: An Immunohistochemical Study on Tissue Microarrays and the Coressponding Whole-Tissue Sections with a Supplemental Fish Study

被引:11
|
作者
Gasljevic, Gorana [1 ]
Lamovec, Janez [1 ]
Contreras, Juan Antonio [1 ]
Zadnik, Vesna [2 ]
Blas, Mateja [1 ]
Gasparov, Slavko [3 ,4 ]
机构
[1] Inst Oncol, Dept Pathol, Ljubljana 1000, Slovenia
[2] Inst Oncol, Canc Registry, Ljubljana 1000, Slovenia
[3] Univ Hosp Merkur, Dept Pathol, Zagreb 10000, Croatia
[4] Univ Zagreb, Sch Med, Zagreb 10000, Croatia
关键词
FISH; Gastric carcinoma; HER2; Immunohistochemistry; TMA; Whole sections; IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; PROGNOSTIC-FACTOR; CARCINOMA; EXPRESSION; ASSOCIATION; VALIDATION; SURVIVAL; RECEPTOR;
D O I
10.1007/s12253-013-9654-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since focal HER2 expression is an issue in GC, TMA construction from the paraffin-embedded surgically-obtained tissue may not reflect its real status. The aim of this study was to assess the HER2 status in tissue microarrays (TMAs) and the corresponding whole sections using HercepTest immunohistochemistry (IHC), and to correlate it and to assess the concordance of HER2 IHC and fluorescence in situ hybridization (FISH) in TMAs. Concordance of the HER2 expression status for 302 cases of gastric cancer using 9 paired TMAs was evaluated using a 2-mm core size and 305 corresponding whole sections. Concordance of the IHC and FISH HER2 status was compared. In addition,, the HER2 status was compared to clinicopathological characteristics and patients' survival. Using the whole-section approach, HER2 over-expression was found in 25.2 % (HER2 3+ 6.6 %, HER2 2+ 18.7 %) of tumours. The overall concordance of IHC between the cores and the whole section was 84.9 %; 15.1 % of the tumours showed HER2 amplification. The overall concordance of IHC and FISH on cores was 75.7 %. The level of amplification correlated with the IHC score. Relationship between the intestinal and papillary types and tumour grade was observed for tumours with over-expression and amplification, whereas tumour location was related only to over-expression. There was a statistically significant difference in the overall survival of the patients, which was related to HER2 amplification. In conclusion, good concordance of the IHC HER2 results between tissue cores in TMA and whole sections, and excellent concordance of the IHC and FISH results on tissue cores was found. At least a part of the observed IHC HER2 heterogeneity could very likely be explained by fixation artifacts. With adequate fixation, a higher concordance of IHC HER2 between the cores and the whole sections can be expected. The TMA approach could enable an easier analysis of more than one representative tumour block.
引用
收藏
页码:855 / 865
页数:11
相关论文
共 50 条
  • [41] HER-2/neu gene amplification in ovarian tumours:: a comprehensive immunohistochemical and FISH analysis on tissue microarrays
    Mayr, D
    Kanitz, V
    Amann, G
    Engel, J
    Burges, A
    Löhrs, U
    Diebold, J
    HISTOPATHOLOGY, 2006, 48 (02) : 149 - 156
  • [42] Trainable Immunohistochemical HER2/neu Image Analysis A Multisite Performance Study Using 260 Breast Tissue Specimens
    Nassar, Aziza
    Cohen, Cynthia
    Agersborg, Sally S.
    Zhou, Weidong
    Lynch, Kathleen A.
    Albitar, Maher
    Barker, Edward A.
    Vanderbilt, Burton L.
    Thompson, Jim
    Heyman, Eugene R.
    Lange, Holger
    Olson, Allen
    Siddiqui, Momin T.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2011, 135 (07) : 896 - 902
  • [43] Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections
    Ye, Min
    Huang, Dan
    Zhang, Qiongyan
    Weng, Weiwei
    Tan, Cong
    Qin, Guangqi
    Jiang, Wenhua
    Sheng, Weiqi
    Wang, Lei
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [44] Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer
    Coronado Martin, Pluvio J.
    Fasero Laiz, Maria
    Garcia Santos, Javier
    Ramirez Mena, Mar
    Vidart Aragon, Jose A.
    MEDICINA CLINICA, 2007, 128 (01): : 1 - 6
  • [45] Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
    Liu, Zhi-Hua
    Wang, Kun
    Lin, Dan-Yi
    Xu, Jie
    Chen, Jie
    Long, Xiao-Yu
    Ge, Yan
    Luo, Xin-Lan
    Zhang, Ke-Ping
    Liu, Yan-Hui
    Xu, Fang-Ping
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 51 - 57
  • [46] Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study
    Gao, Xianchun
    Zhao, Lulu
    Zhang, Nannan
    Han, Weili
    Liu, Kun
    Yan, Junya
    Chen, Ling
    Pan, Yan
    Li, Renlong
    Li, Wenjiao
    Zhang, Haohao
    Li, Hongwei
    Wang, Shibo
    Gao, Xiaoliang
    Niu, Penghui
    Wang, Wanqing
    Ji, Gang
    Zhao, Qingchuan
    Lu, Yuanyuan
    Li, Zengshan
    Shang, Lei
    Liang, Han
    Wu, Kaichun
    Deng, Jingyu
    Chen, Yingtai
    Nie, Yongzhan
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (05) : 1330 - 1341
  • [47] HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study
    Kim, Woo-Ho
    Gomez-Izquierdo, Lourdes
    Vilardell, Felip
    Chu, Kent-Man
    Soucy, Genevieve
    dos Santos, Lucas V.
    Monges, Genevieve
    Viale, Giuseppe
    Brito, Maria Jose
    Osborne, Stuart
    Noe, Johannes
    Du, Xiang
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (04) : 239 - 245
  • [48] HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study
    Huang, Dan
    Lu, Ning
    Fan, Qinhe
    Sheng, Weiqi
    Bu, Hong
    Jin, Xiaolong
    Li, Guimei
    Liu, Yanhui
    Li, Xianghong
    Sun, Wenyong
    Zhang, Huizhong
    Li, Xiaobing
    Zhou, Zongguang
    Yan, Min
    Wang, Xuan
    Sha, Weihong
    Ji, Jiafu
    Cheng, Xiangdong
    Zhou, Zhiwei
    Xu, Jianming
    Du, Xiang
    PLOS ONE, 2013, 8 (11):
  • [49] Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study
    Francz, Monika
    Egervari, Kristof
    Kardos, Laszlo
    Toth, Judit
    Nemes, Zoltan
    Szanto, Janos
    Szollosi, Zoltan
    JOURNAL OF CLINICAL PATHOLOGY, 2010, 63 (04) : 341 - 346
  • [50] HER2 amplification and overexpression is not present in pediatric osteosarcoma:: A tissue microarray study
    Somers, GR
    Ho, M
    Zielenska, M
    Squire, JA
    Thorner, PS
    PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2005, 8 (05) : 525 - 532